Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Investor's Business Daily on MSN17h
Amgen Shrugs Off A Surprise Setback For One Of Its Obesity DrugsAmgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback